NCT04584255

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: ACTIVE_NOT_RECRUITING

Phase: PHASE2

Sponsor: Dana-Farber Cancer Institute

Condition: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: primary_completion_date_past_signal | long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.